Payment overview · 2025
General Payments
$15,885.29
116 reported records · 17 companies
Healthcare provider profile · identity verified
Thomas M Buzbee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TYLER, TX · NPI 1770682619
Verified facts
What the public records show
CMS Open Payments records show Thomas M Buzbee, M.D. received $15,885.29 in general payments during 2025 across 116 reported records.
Amgen Inc. accounted for 93.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 570 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 829 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $14,786.29 | 93.1% | 32 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $241.38 | 1.5% | 21 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $179.81 | 1.1% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.76 | 1.1% | 23 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $97.50 | 0.6% | 6 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $93.28 | 0.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $80.76 | 0.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.59 | 0.3% | 3 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $26.07 | 0.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.32 | 0.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.04 | 0.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.20 | 0.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.56 | 0.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.40 | 0.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.98 | 0.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.67 | 0.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.68 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,000.00 | 9 |
| Food and Beverage | $1,715.65 | 105 |
| Travel and Lodging | $145.60 | 1 |
| Education | $24.04 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14,716.37 | 24 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $138.36 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $106.14 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $100.92 | 12 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $97.50 | 6 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $93.28 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $80.76 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $74.70 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.66 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.47 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $59.16 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.59 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $41.45 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $39.81 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $39.81 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.06 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.81 | 3 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $26.07 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $23.97 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.58 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $4.49 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $3.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 829 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 570 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
161 | 46 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
158 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
172 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
570 | 106 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
72 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
829 | 127 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
40 | 40 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2016 | 539 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1985 | 504 |
| Amlodipine Besylate | Amlodipine Besylate | 1657 | 424 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1327 | 374 |
| Potassium Chloride | Potassium Chloride | 1290 | 298 |
| Losartan Potassium | Losartan Potassium | 1262 | 351 |
| Gabapentin | Gabapentin | 897 | 208 |
| Pantoprazole Sodium | Pantoprazole Sodium | 891 | 232 |
| Omeprazole | Omeprazole | 850 | 241 |
| Eliquis | Apixaban | 829 | 127 |
| Ezetimibe | Ezetimibe | 726 | 182 |
| Lisinopril | Lisinopril | 687 | 173 |
| Simvastatin | Simvastatin | 640 | 173 |
| Carvedilol | Carvedilol | 633 | 157 |
| Trazodone Hcl | Trazodone Hcl | 630 | 146 |
| Tamsulosin Hcl | Tamsulosin Hcl | 605 | 167 |
| Memantine Hcl | Memantine Hcl | 589 | 108 |
| Escitalopram Oxalate | Escitalopram Oxalate | 576 | 128 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 572 | 115 |
| Ozempic | Semaglutide | 570 | 106 |
| Metoprolol Succinate | Metoprolol Succinate | 534 | 150 |
| Donepezil Hcl | Donepezil Hcl | 492 | 98 |
| Sertraline Hcl | Sertraline Hcl | 471 | 109 |
| Furosemide | Furosemide | 461 | 107 |
| Metoprolol Tartrate | Metoprolol Tartrate | 416 | 112 |
| Glimepiride | Glimepiride | 405 | 114 |
| Allopurinol | Allopurinol | 380 | 77 |
| Montelukast Sodium | Montelukast Sodium | 368 | 103 |
| Metformin Hcl | Metformin Hcl | 351 | 97 |
| Torsemide | Torsemide | 339 | 93 |
| Clopidogrel | Clopidogrel Bisulfate | 330 | 85 |
| Meloxicam | Meloxicam | 330 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 316 | 95 |
| Quetiapine Fumarate | Quetiapine Fumarate | 307 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 305 | 62 |
| Spironolactone | Spironolactone | 296 | 84 |
| Mirtazapine | Mirtazapine | 292 | 68 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 282 | 74 |
| Repatha Sureclick | Evolocumab | 280 | 42 |
| Finasteride | Finasteride | 273 | 66 |
| Lorazepam | Lorazepam | 253 | 76 |
| Tramadol Hcl | Tramadol Hcl | 249 | 80 |
| Xarelto | Rivaroxaban | 243 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 235 | 87 |
| Bupropion Xl | Bupropion Hcl | 231 | 58 |
| Alprazolam | Alprazolam | 229 | 88 |
| Famotidine | Famotidine | 229 | 56 |
| Celecoxib | Celecoxib | 228 | 80 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 218 | 31 |
| Jardiance | Empagliflozin | 211 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 208 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 206 | 58 |
| Divalproex Sodium | Divalproex Sodium | 191 | 34 |
| Prednisone | Prednisone | 187 | 96 |
| Methylprednisolone | Methylprednisolone | 177 | 159 |
| Farxiga | Dapagliflozin Propanediol | 172 | 31 |
| Cefdinir | Cefdinir | 170 | 130 |
| Synthroid | Levothyroxine Sodium | 161 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 159 | 45 |
| Mounjaro | Tirzepatide | 158 | 35 |
| Myrbetriq | Mirabegron | 158 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 53 |
| Azithromycin | Azithromycin | 154 | 124 |
| Estradiol | Estradiol | 154 | 46 |
| Atenolol | Atenolol | 152 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 152 | 43 |
| Buspirone Hcl | Buspirone Hcl | 151 | 35 |
| Nebivolol Hcl | Nebivolol Hcl | 150 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 140 | 37 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 137 | 81 |
| Hydralazine Hcl | Hydralazine Hcl | 136 | 32 |
| Temazepam | Temazepam | 136 | 50 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 134 | 89 |
| Citalopram Hbr | Citalopram Hydrobromide | 134 | 33 |
| Alendronate Sodium | Alendronate Sodium | 130 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 127 | 25 |
| Ondansetron Odt | Ondansetron | 126 | 67 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 125 | 36 |
| Levetiracetam | Levetiracetam | 125 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 121 | 33 |
| Benazepril Hcl | Benazepril Hcl | 119 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 114 | 31 |
| Clonazepam | Clonazepam | 112 | 45 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 111 | 62 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 107 | 21 |
| Methenamine Hippurate | Methenamine Hippurate | 107 | 17 |
| Cefuroxime | Cefuroxime Axetil | 105 | 72 |
| Clonidine Hcl | Clonidine Hcl | 104 | 49 |
| Levofloxacin | Levofloxacin | 103 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 29 |
| Fenofibrate | Fenofibrate | 100 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 100 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 98 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 98 | 63 |
| Ipratropium Bromide | Ipratropium Bromide | 96 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 95 | 16 |
| Propranolol Hcl | Propranolol Hcl | 95 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 29 |
| Irbesartan | Irbesartan | 89 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 26 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 85 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 85 | 19 |
| Pregabalin | Pregabalin | 83 | 34 |
| Valacyclovir | Valacyclovir Hcl | 83 | 40 |
| Metformin Hcl Er | Metformin Hcl | 82 | 22 |
| Januvia | Sitagliptin Phosphate | 79 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 79 | 19 |
| Repatha Syringe | Evolocumab | 79 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 78 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 77 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 77 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 17 |
| Megestrol Acetate | Megestrol Acetate | 73 | 31 |
| Rybelsus | Semaglutide | 72 | 11 |
| Olanzapine | Olanzapine | 70 | 20 |
| Azelastine Hcl | Azelastine Hcl | 69 | 30 |
| Ibandronate Sodium | Ibandronate Sodium | 66 | 27 |
| Sucralfate | Sucralfate | 65 | 14 |
| Verapamil Er | Verapamil Hcl | 65 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 43 |
| Chlorthalidone | Chlorthalidone | 63 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 32 |
| Amiodarone Hcl | Amiodarone Hcl | 62 | 12 |
| Cephalexin | Cephalexin | 62 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 62 | 44 |
| Venlafaxine Hcl | Venlafaxine Hcl | 62 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 61 | 15 |
| Midodrine Hcl | Midodrine Hcl | 60 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 59 | 14 |
| Linzess | Linaclotide | 58 | 11 |
| Nystatin | Nystatin | 58 | 39 |
| Permethrin | Permethrin | 58 | 30 |
| Tresiba Flextouch U-100 | Insulin Degludec | 58 | 12 |
| Gemtesa | Vibegron | 56 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 56 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 55 | 16 |
| Multaq | Dronedarone Hcl | 55 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 55 | 30 |
| Testosterone Cypionate | Testosterone Cypionate | 55 | 35 |
| Clonidine | Clonidine | 54 | suppressed |
| Latanoprost | Latanoprost | 54 | 12 |
| Aripiprazole | Aripiprazole | 53 | 14 |
| Entresto | Sacubitril/Valsartan | 51 | 13 |
| Lamotrigine | Lamotrigine | 51 | suppressed |
| Praluent Pen | Alirocumab | 51 | 12 |
| Ramipril | Ramipril | 51 | 16 |
| Trulicity | Dulaglutide | 50 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 35 |
| Lansoprazole | Lansoprazole | 49 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 49 | suppressed |
| Methotrexate | Methotrexate Sodium | 46 | 11 |
| Digoxin | Digoxin | 45 | 12 |
| Flecainide Acetate | Flecainide Acetate | 45 | suppressed |
| Humalog | Insulin Lispro | 45 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 45 | 12 |
| Rexulti | Brexpiprazole | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 42 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 42 | suppressed |
| Novolog | Insulin Aspart | 42 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 42 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 41 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 41 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 41 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 41 | suppressed |
| Valsartan | Valsartan | 41 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 40 | 40 |
| Eszopiclone | Eszopiclone | 39 | 20 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 39 | suppressed |
| Methocarbamol | Methocarbamol | 39 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Primidone | Primidone | 39 | suppressed |
| Risperidone | Risperidone | 39 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 38 | 27 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Acyclovir | Acyclovir | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Lumigan | Bimatoprost | 36 | suppressed |
| Invokana | Canagliflozin | 35 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 35 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 34 | 29 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 17 |
| Nifedipine Er | Nifedipine | 34 | 12 |
| Telmisartan | Telmisartan | 34 | 11 |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 17 |
| Topiramate | Topiramate | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Sotalol | Sotalol Hcl | 32 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Baclofen | Baclofen | 31 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 15 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | 14 |
| Anastrozole | Anastrozole | 29 | suppressed |
| Diazepam | Diazepam | 29 | 18 |
| Fluconazole | Fluconazole | 29 | 25 |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | 12 |
| Silodosin | Silodosin | 29 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | 11 |
| Methimazole | Methimazole | 28 | suppressed |
| Trulance | Plecanatide | 28 | suppressed |
| Armour Thyroid | Thyroid,pork | 27 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 26 | suppressed |
| Metronidazole | Metronidazole | 25 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 17 |
| Insulin Lispro | Insulin Lispro | 24 | suppressed |
| Minoxidil | Minoxidil | 24 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Levemir | Insulin Detemir | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 22 | suppressed |
| Mirabegron Er | Mirabegron | 22 | 12 |
| Klor-Con 10 | Potassium Chloride | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Admelog Solostar | Insulin Lispro | 20 | suppressed |
| Felodipine Er | Felodipine | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 14 |
| Acetazolamide Er | Acetazolamide | 19 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 19 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Haloperidol | Haloperidol | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Pentoxifylline | Pentoxifylline | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Indapamide | Indapamide | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Cefadroxil | Cefadroxil | 16 | 14 |
| Cilostazol | Cilostazol | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | 14 |
| Folic Acid | Folic Acid | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Np Thyroid | Thyroid,pork | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 14 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15,885.29 · 116 records | Amgen Inc. | AIRSUPRA, CRENESSITY, CREON, DUROLANE, Dexcom G6 Transmitter, ELIQUIS, EVENITY, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, Symbravo, TEPEZZA, THINPREP 2000 PROCESSOR, TZIELD, UBRELVY, VRAYLAR, VYEPTI, VYNDAQEL, Veozah, WaveWriter Alpha Prime 16, Wegovy, ZAVZPRET | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error